Researchers at City of Hope have developed a new 'plug-and-play' technology for CAR T cell therapy. The approach adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment.
This post-treatment addition is intended to give scientists better control over the cells. According to the report, it allows them to redirect the T cells to attack different types of cancer, potentially adapting to changes in the disease.
The technology is described as 'plug-and-play,' implying that new targeting molecules can be inserted as needed. Because this article is based on a single source, there are no conflicting accounts to note; the description reflects the researchers' own claims.